About Retrotope
Retrotope is a Healthcare company based in Los Altos (United States) founded in 2006 by Mikhail S Shchepinov and Charles Cantor. Therapeutics for neurodegenerative and ophthalmological diseases are developed. Retrotope has raised $58.58 million across 7 funding rounds from investors including MP Advisors, Timur Artemev and Morningside China. The company has since been acquired. Retrotope offers products and services including RT001 and RT011. Its focus areas include Life Sciences, Rare Diseases, Drugs and CNS. Its legal entity is Retrotope Inc. Its competitors include Harmony Biosciences, QurAlis and Passage Bio; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2006 and headquartered in Los Altos, United States, therapeutics are developed by Retrotope to address neurodegenerative and ophthalmological diseases. A proprietary drug discovery platform is utilized to produce disease-modifying drugs that target oxidative stress and cellular degeneration from lipid peroxidation. Lead candidates include RT001 for infantile neuroaxonal dystrophy, Friedreichs ataxia, and amyotrophic lateral sclerosis, alongside RT011 for dry age-related macular degeneration and geographic atrophy.
- Headquarters Los Altos, United States
- Founders Mikhail S Shchepinov, Charles Cantor
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website retrotope.com
- Social LinkedIn X Facebook
- Legal Name Retrotope Inc.
- Total Equity Funding$58.58M (USD)
in 7 rounds
- Latest Funding Round$13.3M (USD), Series D
Jan 2021
- InvestorsMP Advisors
& 6 more
Products & Services of Retrotope
Retrotope offers a comprehensive portfolio of products and services, including RT001 and RT011.
Stabilized Linoleic Acid for treating infantile neuroaxonal dystrophy and other diseases.
Stabilized Docosahexaenoic acid for dry age-related macular degeneration.
Funding Insights of Retrotope
Retrotope has successfully raised a total of $58.58M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $13.3 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $58.58M
- Total Rounds 7
- Last Round Series D — $13.3M
- First Round $14.53M
(Mar 2016)
- Investors Count 7
All 7 funding rounds of Retrotope with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $13.3M | Series D | – | – | – |
| Jul 2019 | $4.07M | Series C | – | – | – |
| Jul 2019 | $20M | Series C | – | Timur Artemev, MP Advisors | |
| Dec 2018 | $4.33M | Series B | – | – | – |
| Jan 2018 | $2.35M | Series B | – | – | – |
| Nov 2016 | $2.73M | Debt – Conventional | – | – | – |
| Mar 2016 | $14.53M | Series B | – | North Texas Angel Network, Green Park & Golf Ventures |
7 investors in total: 6 institutional and 1 angel.
Investors in Retrotope
Retrotope has secured backing from 7 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include MP Advisors, Timur Artemev and Morningside China.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences startups are funded by a non-profit angel network. | lifescienceangels.com | Sunnyvale, United States | ||
Early-stage companies are supported through angel investment funding. | northtexasangels.org | Dallas, United States | ||
Early-stage venture capital investments are made in medical startups. | 2011 | gpgventures.com | Dallas, United States | |
Early Stage VC firm investing in the US & India | sdlventures.com | Los Altos, United States | ||
Offers biopharma consulting, strategic advisory, research, and investment services worldwide. | 1996 | mpadvisor.com | Vadodara, India | |
VC and private equity investments are made in China-US companies. | morningside.com.cn | Shanghai, China | ||
TA Timur Artemev | Angel investor and entrepreneur, co-founder of Monedo, active in Indian startups | unknown_7e68d3b587ad49e1b |
Investor details for Retrotope
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Retrotope
4 people are tracked at Retrotope (2 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Mikhail S Shchepinov | Founder | Leadership |
Charles Cantor | Co-Founder | Leadership |
Karsten Schmidt | SVP, Opthalmology | Team |
Vidhya Gopalakrishnan | CDO | Team |
Complete people profiles for Retrotope
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Retrotope
3 dated milestones of Retrotope across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Retrotope is founded.
- Funding First funding round of $14.5M.
- Funding Latest funding round, Series D, of $13.3M.
Competitors of Retrotope
Retrotope has 3 listed competitors in our database, 3 of them funded. They include Harmony Biosciences, QurAlis and Passage Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| harmonybiosciences.com | 2017 | Plymouth Meeting, United States | $345M | 246 | Developer of therapeutics for rare neurological diseases | |
| quralis.com | 2016 | Cambridge, United States | $155.45M | 38 | Drugs and CSF devices are developed for ALS treatment. | |
| passagebio.com | 2017 | Philadelphia, United States | $225.5M | 58 | Gene therapies for CNS rare diseases are developed. |
Detailed competitors of Retrotope
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Retrotope
Websites that share an audience with Retrotope (retrotope.com).
Websites whose visitors overlap most with Retrotope. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details |
Top companies in Rare Diseases
3 companies that operate in the same segment as Retrotope (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Retrotope
Complete news archive for Retrotope
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Retrotope
Retrotope was founded in 2006 and raised its 1st funding round 10 years after it was founded.
Retrotope is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.
Retrotope is a funded company, having raised a total of $58.58M across 7 funding rounds to date. The company's 1st funding round was a Series B of $14.53M, raised on Mar 2016.
Founded in 2006 and headquartered in Los Altos, United States, therapeutics are developed by Retrotope to address neurodegenerative and ophthalmological diseases. A proprietary drug discovery platform is utilized to produce disease-modifying drugs that target oxidative stress and cellular degeneration from lipid peroxidation. Lead candidates include RT001 for infantile neuroaxonal dystrophy, Friedreichs ataxia, and amyotrophic lateral sclerosis, alongside RT011 for dry age-related macular degeneration and geographic atrophy.
Retrotope's top competitors include Harmony Biosciences, QurAlis and Passage Bio.
Retrotope offers RT001 and RT011.
Retrotope has 7 investors. Key investors include MP Advisors, Timur Artemev, Morningside China, Life Science Angels, and North Texas Angel Network.
Retrotope operates through Retrotope Inc..